Rhumbline Advisers Acquires 1,746 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Rhumbline Advisers increased its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 139,088 shares of the medical technology company’s stock after acquiring an additional 1,746 shares during the quarter. Rhumbline Advisers’ holdings in Alphatec were worth $1,277,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ATEC. State Street Corp grew its position in Alphatec by 10.1% during the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock worth $17,453,000 after purchasing an additional 287,350 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after buying an additional 297,850 shares during the last quarter. Royce & Associates LP increased its position in shares of Alphatec by 15.9% in the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock valued at $6,740,000 after acquiring an additional 165,954 shares during the period. Walleye Capital LLC raised its stake in Alphatec by 3.2% in the 3rd quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company’s stock worth $5,902,000 after acquiring an additional 32,529 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Alphatec by 1.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 823,222 shares of the medical technology company’s stock worth $4,577,000 after acquiring an additional 15,577 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Wall Street Analysts Forecast Growth

ATEC has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Piper Sandler increased their price objective on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Alphatec in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Insider Buying and Selling

In other news, CEO Patrick Miles sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the transaction, the chief executive officer now owns 6,152,544 shares of the company’s stock, valued at approximately $74,015,104.32. This trade represents a 0.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the sale, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 290,898 shares of company stock valued at $3,327,710. Company insiders own 22.80% of the company’s stock.

Alphatec Stock Performance

Shares of Alphatec stock opened at $11.44 on Thursday. The firm has a market cap of $1.65 billion, a PE ratio of -8.94 and a beta of 1.43. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $14.88. The business’s fifty day simple moving average is $10.81 and its 200-day simple moving average is $8.53.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. Equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.